Seagen and astellas complete enrollment in ev-103 trial cohort k combining padcev® (enfortumab vedotin-ejfv) with pembrolizumab as first-line treatment for advanced urothelial cancer

Bothell, wash. & tokyo--(business wire)--seagen inc. (nasdaq:sgen) and astellas pharma inc. (tse:4503, president and ceo: kenji yasukawa, ph.d., “astellas”) today announced that patient enrollment was completed in cohort k of the phase 1b/2 ev-103 clinical trial (also known as keynote-869). the cohort is evaluating padcev® (enfortumab vedotin-ejfv) in combination with merck's anti-pd-1 therapy keytruda® (pembrolizumab) as first-line treatment in patients with unresectable locally advanced or me
SGEN Ratings Summary
SGEN Quant Ranking